Tags

Type your tag names separated by a space and hit enter

Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline.
Angiology. 1989 Jul; 40(7):639-49.A

Abstract

A multicenter, prospective, placebo-controlled, double-blind trial was conducted to investigate the efficacy of intravenous infusion therapy with pentoxifylline over fourteen days in patients suffering from angiographically confirmed chronic peripheral occlusive arterial disease, Fontaine stage II, with at least a six-month history. After a washout phase of one week, the patients received in accordance with a randomization scheme either an i.v. infusion of 300 mg of pentoxifylline (15 mL ampoules) or 15 mL of a 0.9% NaCl solution in 250 mL of 5% laevulose, administered over three hours twice daily. The main efficacy parameters were treadmill-assessed initial claudication distance (ICD) and absolute claudication distance (ACD). Baseline testing revealed a mean ICD of 131 m in the pentoxifylline group and 126 m in the placebo cohort; mean ACD values were 239 m and 225 m respectively. The group of patients treated with pentoxifylline (n = 75) displayed a significantly greater improvement (p less than 0.0001) in ICD (+70%) and ACD (+60%) than the placebo group did (+33%) and 32%, respectively) (n = 79). The infusions were well tolerated in both groups.

Authors+Show Affiliations

Department of Internal Medicine, University Ulm, West Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

2662830

Citation

Rudofsky, G, et al. "Intravenous Treatment of Chronic Peripheral Occlusive Arterial Disease: a Double-blind, Placebo-controlled, Randomized, Multicenter Trial of Pentoxifylline." Angiology, vol. 40, no. 7, 1989, pp. 639-49.
Rudofsky G, Haussler KF, Künkel HP, et al. Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline. Angiology. 1989;40(7):639-49.
Rudofsky, G., Haussler, K. F., Künkel, H. P., Schneider-May, H., Spengel, F., Symann, O., & Werner, H. J. (1989). Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline. Angiology, 40(7), 639-49.
Rudofsky G, et al. Intravenous Treatment of Chronic Peripheral Occlusive Arterial Disease: a Double-blind, Placebo-controlled, Randomized, Multicenter Trial of Pentoxifylline. Angiology. 1989;40(7):639-49. PubMed PMID: 2662830.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline. AU - Rudofsky,G, AU - Haussler,K F, AU - Künkel,H P, AU - Schneider-May,H, AU - Spengel,F, AU - Symann,O, AU - Werner,H J, PY - 1989/7/1/pubmed PY - 1989/7/1/medline PY - 1989/7/1/entrez SP - 639 EP - 49 JF - Angiology JO - Angiology VL - 40 IS - 7 N2 - A multicenter, prospective, placebo-controlled, double-blind trial was conducted to investigate the efficacy of intravenous infusion therapy with pentoxifylline over fourteen days in patients suffering from angiographically confirmed chronic peripheral occlusive arterial disease, Fontaine stage II, with at least a six-month history. After a washout phase of one week, the patients received in accordance with a randomization scheme either an i.v. infusion of 300 mg of pentoxifylline (15 mL ampoules) or 15 mL of a 0.9% NaCl solution in 250 mL of 5% laevulose, administered over three hours twice daily. The main efficacy parameters were treadmill-assessed initial claudication distance (ICD) and absolute claudication distance (ACD). Baseline testing revealed a mean ICD of 131 m in the pentoxifylline group and 126 m in the placebo cohort; mean ACD values were 239 m and 225 m respectively. The group of patients treated with pentoxifylline (n = 75) displayed a significantly greater improvement (p less than 0.0001) in ICD (+70%) and ACD (+60%) than the placebo group did (+33%) and 32%, respectively) (n = 79). The infusions were well tolerated in both groups. SN - 0003-3197 UR - https://www.unboundmedicine.com/medline/citation/2662830/Intravenous_treatment_of_chronic_peripheral_occlusive_arterial_disease:_a_double_blind_placebo_controlled_randomized_multicenter_trial_of_pentoxifylline_ L2 - http://journals.sagepub.com/doi/full/10.1177/000331978904000706?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -